Comment on CMS-2026-1255-0001

Summary: McKesson Corporation supports the proposed rule to expand interoperability and electronic prior authorization (ePA) requirements to prescription drugs to reduce administrative burden. They advocate for a dual-standard framework (FHIR and NCPDP), phased implementation timelines, and the inclusion of non-EHR workflows to ensure the rule reflects real-world pharmacy and provider operations.